The FDA and EMA have set out updated regulatory agendas that will shape biologics manufacturing standards in coming years. The FDA’s Center for Biologics Evaluation and Research (CBER) 2026 agenda ...
The growing complexity of the field reinforces the need for standards ensuring product quality, consistency, and patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results